lorvotuzumab mertansine

Home
Ligands
lorvotuzumab mertansine

GtoPdb Ligand ID: 7431

Synonyms: BB-10901 | IMGN901

Comment: Lorvotuzumab mertansine is an antibody-drug conjugate (ADC) combining an anti-NCAM1 (CD56) monoclonal antibody with the maytansinoid DM1 (PubChem CID 71301226) tubulin inhibitor [2].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-db record. Patent US5639641 [4] describes the resurfacing of murine anti-CD56 monoclonal antibody N901, to improve its therapeutic efficacy in preparation for use as a human drug. A protein BLAST search matches the variable region of the light chain of lorvotuzumab, with sequence 36 from the patent, sequence 36 being a CDR grafted version of N901. No affinity data for the interaction between the preferred engineered antibody and the molecular target is provided in the patent.

References
1. Ishitsuka K, Jimi S, Goldmacher VS, Ab O, Tamura K. (2008) Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy. Br J Haematol, 141 (1): 129-31. [PMID:18279455]
2. Lambert JM. (2013) Drug-conjugated antibodies for the treatment of cancer. Br J Clin Pharmacol, 76 (2): 248-62. [PMID:23173552]
3. Lutz RJ, Whiteman KR. (2009) Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs, 1 (6): 548-51. [PMID:20068397]
4. Pedersen JT, Searle SMJ, Rees AR, Roguska MA, Guild BC. (1997) Resurfacing of rodent antibodies. Patent number: US5639641. Assignee: Immunogen Inc.. Priority date: 09/09/1999. Publication date: 17/06/1997.
5. van de Donk NW, Lokhorst HM. (2013) New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients. Expert Opin Pharmacother, 14 (12): 1569-73. [PMID:23721099]
6. Whiteman KR, Johnson HA, Mayo MF, Audette CA, Carrigan CN, LaBelle A, Zukerberg L, Lambert JM, Lutz RJ. (2014) Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models. MAbs, 6 (2): 556-66. [PMID:24492307]

References

1. Ishitsuka K, Jimi S, Goldmacher VS, Ab O, Tamura K. (2008)
Targeting CD56 by the maytansinoid immunoconjugate IMGN901 (huN901-DM1): a potential therapeutic modality implication against natural killer/T cell malignancy.
Br J Haematol, 141 (1): 129-31. [PMID:18279455]

2. Lambert JM. (2013)
Drug-conjugated antibodies for the treatment of cancer.
Br J Clin Pharmacol, 76 (2): 248-62. [PMID:23173552]

3. Lutz RJ, Whiteman KR. (2009)
Antibody-maytansinoid conjugates for the treatment of myeloma.
MAbs, 1 (6): 548-51. [PMID:20068397]

4. Pedersen JT, Searle SMJ, Rees AR, Roguska MA, Guild BC. (1997)
Resurfacing of rodent antibodies.
Patent number: US5639641. Assignee: Immunogen Inc.. Priority date: 09/09/1999. Publication date: 17/06/1997.

5. van de Donk NW, Lokhorst HM. (2013)
New developments in the management and treatment of newly diagnosed and relapsed/refractory multiple myeloma patients.
Expert Opin Pharmacother, 14 (12): 1569-73. [PMID:23721099]

6. Whiteman KR, Johnson HA, Mayo MF, Audette CA, Carrigan CN, LaBelle A, Zukerberg L, Lambert JM, Lutz RJ. (2014)
Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models.
MAbs, 6 (2): 556-66. [PMID:24492307]